LOGIN
PREVENT CLOT Trial: Aspirin vs. Low Molecular Weight Heparin for Thromboprophylaxis After Fracture
October 2023
PREVENT CLOT Trial: Aspirin vs. Low Molecular Weight Heparin for Thromboprophylaxis After Fracture
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture
N Engl J Med. 2023 Jan 19;388(3): 203-213.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
12,211 patients from 21 trauma centers in the United States and Canada were included in this non-inferiority randomized trial comparing aspirin (n=6,101) and low molecular-weight heparin (n=6110). The primary outcome of interest was death by any cause at 90 days. Secondary outcomes of interest included the risk of thromboembolic events (pulmonary embolism; deep-vein thrombosis), cause-specific dea...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.